Key Statistics
Client
Merck Group
PM Group Office
China
Cost
€34m (Phase 2)
Size
38,000 sqm

Merck is a leading science and technology company in healthcare, life science and performance materials. They are looking to expand their footprint in China and grow their business in this vibrant economy. Merck's new oral solid dosage (OSD) manufacturing and packaging facility in Nantong is Merck's largest outside of Europe.

Do you have a pharmaceutical project? Talk to one of our experts.

Andy Rayner
Andy Rayner

Pharmaceutical Sector Director

The project

PM Group provided full engineering, procurement and construction management (EPCM) for Phase 2 of the new oral solid dosage (OSD) manufacturing and packaging facility.

The scope of the Phase 2 project was to provide additional bulk tableting production and packaging equipment. At the same time modifications to the utilities needed to be made. To meet the Phase 2 production capacity, the administration building was extended and the canteen was completely refitted and enlarged.

Construction around a live facility

Phase 1 which involved the creation of a production train for registration batches, was completed in 2016. The main challenge for Phase 2 was how to work around this live GMP facility. Regulatory authority audits on Phase 1 continued throughout the construction period. Shut downs were minimised by the installation of a 'clean room within a clean room'. This protected the live GMP facility and allowed the maximum level of production to continue during the build. With the HVAC modifications in place, we were able to guarantee regulatory compliance.

 

Health and safety innovation

Environmental Health & Safety was the central focus for both Merck and PM Group. A big issue in this area was the safe installation of equipment on a very busy site without affecting the schedule. Our solution was to install a permanent three story lifting platform. This innovation has helped avoid a clash with site traffic and will help with the safe management of the facility into operation. We are on schedule and are tracking under budget for the Phase 2 project.

Andy Rayner

Pharmaceutical Sector Director